Valenza MN
Brief description of study
The purpose of the study is to define the safety and tolerability of ascending doses of VB119 in subjects with primary membranous nephropathy. Study drug will be administered intravenously. The Data Review Committee will review safety data and determine dosage based on available safety, PD and other clinical data. Participants may be in study for up to 88 weeks.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
